Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption.

Cancer cell·2026
Same author

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study.

Diabetes, obesity & metabolism·2026
Same author

The illusory correlation between geometrical similarity and physician satisfaction in heart auto-segmentation revealed by a physician-blind test.

Journal of applied clinical medical physics·2026
Same author

2D MoS<sub>2</sub>-conformal 3D-printed platform for dual-phototherapy and bone regeneration.

Nano convergence·2026
Same author

Salivary Enzyme-Responsive Switching Nanoparticles Overcoming Diffusion and Absorption Barriers for Transmucosal Delivery.

ACS applied materials & interfaces·2026
Same author

Age-Related Testosterone Decline and Metabolic Determinants in 27,687 Korean Men Aged ≥40 Years: A Nationwide Population-Based Study.

The world journal of men's health·2026

Related Experiment Video

Updated: Mar 16, 2026

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

3.6K

Multistimuli-Responsive Bilirubin Nanoparticles for Anticancer Therapy.

Yonghyun Lee1, Soyoung Lee1, Dong Yun Lee1

  • 1KAIST Institute for the BioCentury, Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Daejeon, 34141, Republic of Korea.

Angewandte Chemie (International Ed. in English)
|August 4, 2016
PubMed
Summary

New bilirubin nanoparticles (BRNPs) offer stimuli-responsive drug delivery for cancer. These nanoparticles release drugs on demand and possess their own anticancer properties, improving treatment efficacy.

Keywords:
anticancer therapybilirubindrug deliverynanomedicinenanoparticles

More Related Videos

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.6K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.6K

Related Experiment Videos

Last Updated: Mar 16, 2026

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

3.6K
Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.6K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.6K

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Cancer Therapeutics

Background:

  • Stimuli-responsive materials show promise for cancer drug delivery but face clinical translation challenges.
  • Ideal drug carriers require biocompatibility, controlled release, scalability, and intrinsic anticancer activity.
  • Bilirubin, an endogenous antioxidant, exhibits anticancer and anti-inflammatory properties.

Purpose of the Study:

  • To develop novel stimuli-responsive nanoparticles from bilirubin for enhanced cancer treatment.
  • To investigate the drug release mechanisms triggered by reactive oxygen species (ROS) and laser light.
  • To evaluate the therapeutic efficacy of bilirubin nanoparticles (BRNPs) loaded with doxorubicin (DOX) in a tumor model.

Main Methods:

  • Fabrication of multistimuli-responsive nanoparticles from bilirubin (BRNPs).
  • Encapsulation of doxorubicin (DOX) into BRNPs (DOX@BRNPs).
  • Assessment of drug release kinetics upon exposure to ROS and 650 nm laser irradiation.
  • Evaluation of tumor growth inhibition in a xenograft tumor model using DOX@BRNPs and laser treatment.

Main Results:

  • BRNPs demonstrated rapid drug release upon exposure to ROS or laser light due to altered bilirubin solubility.
  • DOX@BRNPs combined with 650 nm laser irradiation significantly inhibited tumor growth in a xenograft model.
  • Bilirubin nanoparticles exhibited both drug carrier functionality and intrinsic anticancer/anti-inflammatory effects.

Conclusions:

  • Bilirubin nanoparticles (BRNPs) represent a promising platform for stimuli-responsive cancer drug delivery.
  • BRNPs can serve as effective drug carriers and companion therapeutics, enhancing cancer treatment outcomes.
  • The findings support the potential clinical translation of BRNPs for effective cancer therapy.